Genesis Molecular AI
AI and physics for small-molecule design
Ranked #7 in Best AI Drug Discovery Startups.
Genesis Molecular AI, founded in 2019 as Genesis Therapeutics and renamed in October 2025, builds AI models for designing small-molecule drugs. It raised a $200 million Series B in August 2023, co-led by a16z and Menlo Ventures.
At a glance
| Price from | Custom |
| Best for | Drugmakers partnering on small-molecule discovery |
From Genesis Molecular AI's own website.
What stands out
- Partnerships with Eli Lilly, Gilead and Incyte
- Recurring partner payments
Worth knowing
- Own pipeline still early
- Total funding figures vary by source
How it ranks
Genesis Molecular AI is ranked 7th of 10 in Best AI Drug Discovery Startups (Lister Score 89.4).
#7 in Best AI Drug Discovery Startups · Lister Score 89.4
Incyte made a $40 million equity investment in May 2026, alongside an $80 million upfront payment under an expanded collaboration..
| Rank | Best AI Drug Discovery Startups | Score |
|---|---|---|
| 1 | Isomorphic Labs | 97.1 |
| 2 | Xaira Therapeutics | 95.8 |
| 3 | Chai Discovery | 94.6 |
| 4 | Enveda | 93.3 |
| 5 | insitro | 92.0 |
| 6 | Formation Bio | 90.7 |
| 7 | Genesis Molecular AI | 89.4 |
| 8 | BigHat Biosciences | 88.1 |
| 9 | Terray Therapeutics | 86.7 |
| 10 | Cradle | 85.3 |
Frequently asked questions
How does Genesis Molecular AI rank on Lister?
Genesis Molecular AI is ranked 7th of 10 in Best AI Drug Discovery Startups (Lister Score 89.4).
Appears in
Add this badge to your site
If you work at Genesis Molecular AI, paste this code into your website to show where it ranks on Lister. The badge links to the ranking and updates within a day when the rank changes.